Neoadjuvant treatments for triple-negative breast cancer (TNBC)

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies

(2011) Gunter von Minckwitz et al.   BREAST

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

(2011) M. Martin et al.   BREAST CANCER RESEARCH AND TREATMENT

Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

(2011) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes

(2011) Dokyung Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Changing End Points in Breast-Cancer Drug Approval — The Avastin Story

(2011) Ralph B. D'Agostino   NEW ENGLAND JOURNAL OF MEDICINE

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

(2010) X. S. Chen et al.   ANNALS OF ONCOLOGY

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Management of triple negative breast cancer

(2010) Catherine Oakman et al.   BREAST

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

(2010) Jens Huober et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

(2010) Gunter von Minckwitz et al.   BREAST CANCER RESEARCH AND TREATMENT

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment

(2010) Helena R. Chang et al.   CANCER

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Versus Adjuvant Chemotherapy for Triple Negative Breast Cancer

(2010) Carlie R. Kennedy et al.   JOURNAL OF SURGICAL RESEARCH

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A Brown University Oncology Group Study

(2009) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Cancer: A Step Toward Reversing Triple-Negative Paradox

(2008) Rita S. Mehta   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

(2008) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

(2008)   LANCET

Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors

(2008) E. Rivera et al.   ONCOLOGIST